Discover Six Dynamic Trends to Disrupt the Next Generation of Biopharmaceutical Manufacturing

Frost & Sullivan's latest article, Preparing for Next Generation of Biopharmaceutical Manufacturing, analyzes six dynamic trends that will impact the future of biopharmaceutical manufacturing. These include embracing technology advances, next-generation manufacturing methods, cost optimization for clinical development, advances in recombinant DNA technologies, single-use technologies, and process analytics. Frost & Sullivan's latest article,Preparing for Next Generation of...

Frost & Sullivan's latest article, Preparing for Next Generation of Biopharmaceutical Manufacturing, analyzes six dynamic trends that will impact the future of biopharmaceutical manufacturing. These include embracing technology advances, next-generation manufacturing methods, cost optimization for clinical development, advances in recombinant DNA technologies, single-use technologies, and process analytics.

To download the complimentary article, please visit: http://frost.ly/5nw

"Customized technologies are being developed to meet next-generation monoclonal antibody (mAb) therapy process requirements. Complete integrated process workflows will enable biopharmaceutical companies to rapidly create the manufacturing capacity needed for both clinical and commercial production," observed Nitin Naik, Global Practice Area Leader | Healthcare & Life Sciences at Frost & Sullivan. "Once that broader infrastructure and architecture is in place, companies can accelerate their lab-to-manufacturing scale initiatives for a wide range of conditions."

"3M™ Polisher ST enables the transition to single-use membrane chromatography through a novel guanidinium base chemistry and advanced material science. It offers not only economic benefits and versatility but also has specific functional advantages over equivalent packed-bed columns. These include convenience, scalability, and a small footprint," noted Matt Peters | Application Development Specialist at 3M. "3M™ Polisher ST uses only 20 percent of the buffer volume compared to a column of equal capacity, saving time and money."

Overall, biopharmaceutical companies need to review investments beyond the traditional growth levers of clinical and commercial excellence and intensify efforts related to sustainability. The main strategies that will help them achieve this include:

About Frost & Sullivan

For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

Contact:
Mariana Fernandez
Corporate Communications
E: [email protected]
http://ww2.frost.com